Historical sharp drops and downward valuation corrections in Agenus stock are typically triggered by high cash burn rates, clinical trial setbacks, regulatory delays, or dilution pressures resulting from secondary equity offerings and capital-raising initiatives common among pre-revenue clinical-stage biotechnology enterprises.